RSS feed

Publications (original articles or review articles) published in 2023 from OUS - Department of Clinical Cancer Research

19 publications found

Ascierto PA, Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, Chiarion-Sileni V, Dréno B, Dalle S, Schadendorf D, Callahan MK, Nyakas M, Atkinson V, Gomez-Roca CA, Yamazaki N, Tawbi HA, Sarkis N, Warad D, Dolfi S, Mitra P, Suryawanshi S, Grob JJ (2023)
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
J Clin Oncol, 41 (15), 2724-2735
DOI 10.1200/JCO.22.02072, PubMed 36780608

Beck C, Casey NP, Persiconi I, Moharrami NN, Sike A, Jin Y, Kyte JA (2023)
Development of a TGFβ-IL-2/15 Switch Receptor for Use in Adoptive Cell Therapy
Biomedicines, 11 (2)
DOI 10.3390/biomedicines11020459, PubMed 36830995

Dahl AA, Smeland KB, Eikeland S, Fagerli UM, Bersvendsen HS, Fosså A, Kiserud CE (2023)
Work ability and work status changes in long-term Hodgkin lymphoma survivors with focus on late adverse effects
J Cancer Surviv (in press)
DOI 10.1007/s11764-023-01432-y, PubMed 37526861

Elvebakken H, Hjortland GO, Garresori H, Andresen PA, Janssen EAM, Vintermyr OK, Lothe IMB, Sorbye H (2023)
Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms
J Neuroendocrinol, 35 (4), e13256
DOI 10.1111/jne.13256, PubMed 37017614

Entrop JP, Weibull CE, Smedby KE, Jakobsen LH, Øvlisen AK, Glimelius I, Marklund A, Larsen TS, Holte H, Fosså A, Smeland KB, El-Galaly TC, Eloranta S (2023)
Reproduction patterns among non-Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway: A population-based matched cohort study
Br J Haematol, 202 (4), 785-795
DOI 10.1111/bjh.18938, PubMed 37325886

Entrop JP, Weibull CE, Smedby KE, Jakobsen LH, Øvlisen AK, Molin D, Glimelius I, Marklund A, Holte H, Fosså A, Smeland KB, El-Galaly TC, Eloranta S (2023)
Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway-A population-based matched cohort study
Int J Cancer, 153 (4), 723-731
DOI 10.1002/ijc.34552, PubMed 37119033

Gombos A, Goncalves A, Curigliano G, Bartsch R, Kyte JA, Ignatiadis M, Awada A (2023)
How I treat endocrine-dependent metastatic breast cancer
ESMO Open, 8 (2), 100882
DOI 10.1016/j.esmoop.2023.100882, PubMed 36806375

Gulbrandsen MS, Nøding AS, Smeland KB, Eikeland SA, Kiserud CE, Hjermstad MJ, Fosså A (2023)
Health-related quality of life, depressive symptoms, and chronic fatigue in long-term survivors of Hodgkin lymphoma
Leuk Lymphoma, 64 (6), 1139-1150
DOI 10.1080/10428194.2023.2198053, PubMed 37144290

Huuhtanen J, Kasanen H, Peltola K, Lönnberg T, Glumoff V, Brück O, Dufva O, Peltonen K, Vikkula J, Jokinen E, Ilander M, Lee MH, Mäkelä S, Nyakas M, Li B, Hernberg M, Bono P, Lähdesmäki H, Kreutzman A, Mustjoki S (2023)
Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma
J Clin Invest, 133 (6)
DOI 10.1172/JCI164809, PubMed 36719749

Høland M, Berg KCG, Eilertsen IA, Bjerkehagen B, Kolberg M, Boye K, Lingjærde OC, Guren TK, Mandahl N, van den Berg E, Palmerini E, Smeland S, Picci P, Mertens F, Sveen A, Lothe RA (2023)
Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets
EBioMedicine, 97, 104829
DOI 10.1016/j.ebiom.2023.104829, PubMed 37837931

Jenul A, Stokmo HL, Schrunner S, Hjortland GO, Revheim ME, Tomic O (2023)
Novel ensemble feature selection techniques applied to high-grade gastroenteropancreatic neuroendocrine neoplasms for the prediction of survival
Comput Methods Programs Biomed, 244, 107934 (in press)
DOI 10.1016/j.cmpb.2023.107934, PubMed 38016391

Knappskog S, Grob T, Venizelos A, Amstutz U, Hjortland GO, Lothe IM, Kersten C, Hofsli E, Sundlöv A, Elvebakken H, Garresori H, Couvelard A, Svensson J, Sorbye H, Perren A (2023)
Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma
JCO Precis Oncol, 7, e2200336
DOI 10.1200/PO.22.00336, PubMed 36753687

Morken S, Langer SW, Sundlöv A, Vestermark LW, Ladekarl M, Hjortland GO, Svensson JB, Tabaksblat EM, Haslerud TM, Assmus J, Detlefsen S, Couvelard A, Perren A, Sorbye H (2023)
Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms
Br J Cancer (in press)
DOI 10.1038/s41416-023-02462-0, PubMed 37872405

Nilsson K, Klevebro F, Sunde B, Rouvelas I, Lindblad M, Szabo E, Halldestam I, Smedh U, Wallner B, Johansson J, Johnsen G, Aahlin EK, Johannessen HO, Alexandersson von Döbeln G, Hjortland GO, Wang N, Shang Y, Borg D, Quaas A, Bartella I, Bruns C, Schröder W, Nilsson M (2023)
Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial
Ann Oncol, 34 (11), 1015-1024
DOI 10.1016/j.annonc.2023.08.010, PubMed 37657554

Oh DY, Algazi A, Capdevila J, Longo F, Miller W, Chun Bing JT, Bonilla CE, Chung HC, Guren TK, Lin CC, Motola-Kuba D, Shah M, Hadoux J, Yao L, Jin F, Norwood K, Lebellec L (2023)
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study
Cancer, 129 (8), 1195-1204
DOI 10.1002/cncr.34657, PubMed 36748723

Piperno-Neumann S, Carlino MS, Boni V, Loirat D, Speetjens FM, Park JJ, Calvo E, Carvajal RD, Nyakas M, Gonzalez-Maffe J, Zhu X, Shirley MD, Ramkumar T, Fessehatsion A, Burks HE, Yerramilli-Rao P, Kapiteijn E (2023)
A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
Br J Cancer, 128 (6), 1040-1051
DOI 10.1038/s41416-022-02133-6, PubMed 36624219

Robert C, Carlino MS, McNeil C, Ribas A, Grob JJ, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance A, Daud AI, Hamid O, Larkin J, Anderson J, Krepler C, Grebennik D, Long GV (2023)
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
J Clin Oncol, 41 (24), 3998-4003
DOI 10.1200/JCO.22.01599, PubMed 37348035

Venizelos A, Sorbye H, Elvebakken H, Perren A, Lothe IMB, Couvelard A, Hjortland GO, Sundlöv A, Svensson J, Garresori H, Kersten C, Hofsli E, Detlefsen S, Vestermark LW, Ladekarl M, Tabaksblat EM, Knappskog S (2023)
Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms
Endocr Relat Cancer, 30 (10)
DOI 10.1530/ERC-23-0057, PubMed 37410378

Winge-Main A, Robsahm TE, Nyakas M, Festervoll G, Torkilseng E, Thybo S, Pati S, Carroll R (2023)
Long-term outcomes of stage IIB-IV melanoma patients: nationwide data from Norway
Future Oncol, 19 (3), 205-215
DOI 10.2217/fon-2022-0969, PubMed 36974621